Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cediranib + docetaxel
- Development stage
- Phase 1
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Cediranib + docetaxel is an investigational combination therapy evaluated primarily for the treatment of advanced solid tumors, including metastatic castration-resistant prostate cancer. Cediranib is an oral, potent inhibitor of all three vascular endothelial growth factor receptors (VEGFR-1, -2, and -3), thereby inhibiting tumor angiogenesis. Docetaxel is a well-established chemotherapeutic agent (a taxane) that disrupts microtubule function, resulting in cell cycle arrest and apoptosis. The combination aims to exploit both antiangiogenic (cediranib) and cytotoxic (docetaxel) mechanisms for enhanced antitumor efficacy. Clinical data to date suggest limited additional benefit over docetaxel alone with an increased risk of toxicity, especially in the treatment of metastatic castration-resistant prostate cancer.
- Other names
- cediranib maleate + docetaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)
Beyond the preview
Go deeper on cediranib + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cediranib + docetaxel.